ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2018.5750 ETM-0-0-5750 Articles Protective effects of recombinant human brain natriuretic peptide in perioperative period during open heart surgery XuYunbin LiYong BaoWeiguo QiuShi Department of Cardiovascular Surgery, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China Correspondence to: Dr Yunbin Xu, Department of Cardiovascular Surgery, The Second Hospital of Shandong University, 247 Beiyuan Road, Tianqiao, Jinan, Shandong 250033, P.R. China, E-mail: c8499931dileixu@163.com 03 2018 12 01 2018 15 3 2869 2873 10042017 22082017 Copyright: © Xu et al. 2018 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The aim of the present study was to evaluate the protective effects and safety aspects of recombinant human brain natriuretic peptide (rhBNP) on cardiac functions of patients undergoing open-heart surgery during perioperative period. In total, 150 patients undergoing open heart surgery in the Second Hospital of Shandong Universty from August 2015 to July 2016 were randomly divided into control group and observation group each with 75 cases. Patients in control group were treated by routine rehabilitation while patients in the observation group were treated by both the routine rehabilitation and rhBNP. All the observations were made before operation, after operation and 7 days after operation. The changes of N-terminal pro-brain natriuretic peptide (NT-proBNP) of patients, the left ventricular ejection fraction (LVEF), cardiac function [Cardiac output (CO), pulmonary capillary wedge pressure (PAWP) and central venous pressure (CVP)] of patients were measured. Further, respirator support time, ICU stay time, incidence of complications and vital signs (BP, HR, SaO2) of patients in the two groups were also compared. NT-proBNP levels of all patients improved after operation but it decreased in both groups after 7 days of operation. The decrease of NT-proBNP levels in observation group was significantly higher than that of control group. Whereas, LVEF, CO, PAWP and CVP of patients in both the groups increased after operation but effects were significantly higher in the observation group after 7 days of medication. Respirator support time and ICU stay time of patients in observation group were significantly shorter than those in control group, and the incidence of postoperative complications of patients in the observation group were significantly lower than the control group. Moreover, BP, HR and SaO2 of patients in observation group were significantly elevated in comparison to control group (P<0.05). Recombinant human brain natriuretic peptide (rhBNP) could significantly improve the cardiac functions of patients after open heart surgery, and is safe as well as reliable.

 recombinant human brain natriuretic peptide open heart surgery perioperative period cardiac function Introduction

The rapid development of economy and the improvement of people's living standards allow more patients to accept heart surgery for the improvement of quality of life including the heart valve repair or replacement, cardiac surgery and coronary artery bypass grafting (1). The preoperative cardiac reserve functions of patients before the heart surgery are usually poor. Further, the surgical trauma, intraoperative myocardial ischemia and CPB are also prone to myocardial ischemia as well as ischemia reperfusion injury leading to low cardiac output syndrome (2,3). Therefore, it is very important to strengthen the protection of cardiac functions and prevention of the myocardial damage in patients undergoing cardiac surgery. This process would play an important role in improving the success rates of surgery and prognosis (4). Brain natriuretic peptide is a member of natriuretic peptide family. Recombinant human brain natriuretic peptide (rhBNP) is a kind of medicine for the treatment of heart failure, and is a recommended drug for acute as well as chronic heart failure (5). The related research showed that rhBNP has the ability to maintain the normal cardiac output, dilation of the pulmonary circulation/coronary circulation, reduction in cardiac load, protection of ischemic myocardium (5). Moreover, it could also achieve good clinical effects on heart functions after cardiac surgery (5). In the present study, patients were treated with the combination of routine treatment with recombinant human brain natriuretic peptide (rhBNP) after open-heart surgery and the clinical potential of this combination was evaluated.

 Patients and methods <sec> <title>General information

One hundred and fifty patients undergoing open heart surgery in the Second Hospital of Shandong Universty from August 2015 to July 2016 were randomly divided into control group and observation group by computer, with 75 cases in each group. Patients in control group were treated by routine rehabilitation; patients in the observation group were treated by routine rehabilitation and rhBNP. Inclusion criteria: i) heart function grade II–III of American New York Heart Association; ii) cardiopulmonary bypass support for cardiac surgery includes: valve repair or replacement, correction of congenital heart disease, coronary artery and major blood vessel related surgery; and iii) signed informed consent. Exclusion criteria: i) patients with cardiac shock and hypotension (SBP <90 mmHg); ii) severe renal insufficiency; and iii) allergy to the study drug and lactating women. There was no significant difference between the two groups of patients in general information (P>0.05), comparability is shown in Table I. The study was approved by the Ethics Committee of the Second Hospital of Shandong Universty and informed consents were signed by the patients and/or guardians.

 Surgical methods

All patients underwent cardiac surgery with cardiopulmonary bypass support including: valve repair or replacement, repair of congenital heart disease, coronary artery and major blood vessel related surgery. Postoperative patients with tracheal intubation were sent to ICU to monitor the treatment along with maintenance of circulation and smooth respiration. Further, the late extubation extra corporeal circulation machine (German Stockert-sc type) and membrane oxygen device were used in the two groups of patients for the purpose of cardiopulmonary bypass. Compounds sodium chloride (900 ml), dexamethasone (10 mg), mannitol (250 ml) were used as the pre flushing fluids. Natriuretic peptide (Chengdu Nuodikang Biological Pharmaceutical Co. Ltd.: license number: NMPN S20050033) was added in observation group. Usage and dosage: Patients began to use the above dose regime within 24 h after surgery with continuous use of 24–48 h. The recommended medication time was more than 48 h.

 Evaluation criterion

Venous blood 4 ml of patients was collected before operation, after operation and 7 days after the operation. The N-terminal pro-brain natriuretic peptide (NT-proBNP) of patients were detected by automatic chemiluminescence immunoassay. The left ventricular ejection fraction (LVEF) was measured by color Doppler echocardiography before operation, after operation and 7 days after the operation. Cardiac function [cardiac output (CO), pulmonary capillary wedge pressure (PAWP), central venous pressure (CVP)] of patients were recorded and observed before the operation, after the operation and 7 days after the operation. The ventilator support time and ICU retention time of two groups of patients were recorded. The incidence rate of postoperative complications was observed. Blood pressure (BP), heart rate (HR) and blood oxygen saturation (SaO2) were monitored and observed after 7 days of treatment.

 Statistical analysis

SPSS 19.0 (SPSS Inc., Chicago, IL, USA) software was used for data processing. Measurement data are expressed by mean ± SD, with t-test; count data were expressed by ratio with χ2 test, and P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>T-proBNP levels of all patients improved after operation

NT-proBNP levels of patients in both groups decreased 7 days after operation, and the decrease of NT-proBNP level in observation group was significantly higher than control group (P<0.05) (Table II).

 The LVEF of patients in the groups increased after operation

LVEF of patients in observation group was significantly higher than that in control group after 7 days of medication (P<0.05). (Table III).

 Comparison of the heart function indexes of two groups

The indexes of CO, PAWP and CVP were significantly improved in the two groups compared with before operation, and the improvement degree of the observation group was better than that of the control group 7 days after medication (P<0.05) (Figs. 1–3).

 Mechanical ventilation time, ICU indwelling time and postoperative complications of two groups of patients

Compared with the control group, mechanical ventilation time and ICU indwelling time in the observation group were significantly shorter than those in the control group. Further, the incidence of postoperative complications was significantly lower than that of the control group, and the differences were statistically significant (Table IV).

 Comparison of vital signs in two groups of patients during perioperative period

SBP, DBP, HR, and SaO2 indexes of the observation group were significantly better than those of the control group (P<0.05) (Table V).

 Discussion

Cardiac reserve function is often affected after heart surgery due to surgical trauma and myocardial ischemia. Moreover, these patients are prone to myocardial ischemia and ischemia reperfusion injury that in turn leads to a variety of complications like heart failure, endotoxemia, the systemic inflammatory response syndrome and low cardiac output syndromes (6,7). The low cardiac output syndrome is the most severe complication with high mortality, and there are many factors of incidence, such as poor preoperative cardiac function in patients, myocardial ischemia time, poor cardiac malformation correction, intracardiac operation time, aortic clamping time, postoperative blood volume insufficiency, arrhythmia, cardiac tamponade and pulmonary artery hypertension (8). The reduction of the myocardial damage post-cardiac surgery and the protection of heart function have become the focus of clinical attention. Moreover, they have a profound impact on the success rate of surgery and prognosis of patients (9).

The secretion of NT-proBNP in patients with heart disease is closely related to the ventricular pressure load and volume load. When the ventricular wall tension load in patients increases, the NT-proBNP level would rise sharply. Moreover, the monitoring of it could prevent postoperative complications (10,11). Moreover, the plasma NT-proBNP levels of patients would continue to rise after open-heart surgery (12). The results of the present study showed that the NT-proBNP of patients of both groups increased after operation, which might be affected by anesthesia, surgical trauma, hemodynamic abnormalities, inflammatory stimulation, CPB, myocardial damage and decreased contractile ability. However, the levels of NT-proBNP in the two groups began to decrease after 7 days of treatment. This was the result after drug treatment that included inflammatory reaction of patients (13).

The postoperative CO, PAWP and CVP indicators of the two groups of patients were significantly improved and the observation group was significantly better than the control group after 7 days of treatment (P<0.05). The above observation could be justified in the light of the fact that the natriuretic peptide has balanced expansion arteriovenous/coronary artery diastolic function (14). A related study also showed improvements in the hemodynamic parameters after 15 min of treatment (15). The natriuretic peptide could improve the heart rate through the comprehensive effect (16). The results of this study showed that postoperative LVEF were higher than preoperative in the two groups of patients, and the observation group was significantly higher than the control group after 7 days of treatment (P<0.05). Moreover, natriuretic peptide has ability to directly affect myocardial cells, thereby reducing myocardial oxygen consumption, with inhibition of excessive stress reaction of the circulatory system, so as to have a protective effect on the heart (17,18).

In the present study, SBP, DBP, HR, and SaO2 indexes of the observation group were significantly better than those of the control group (P<0.05). This is due to the natriuretic peptide that has positive chronotropic effect, which not only caused reflex tachycardia, but also inhibited cardiac sympathetic nerve activity, thereby adjusted the blood pressure (19). Moreover, ICU indwelling time and ventilator support were also reduced via natriuretic peptide treatment. In summary, recombinant human brain natriuretic peptide (rhBNP) could protect the cardiac functions of patients after open-heart surgery, and it is safe and reliable. However, for the concrete conclusions, the study needs further exploration in future as the sample size and time were limited in the present study.

 References PontoniGFerrariSGabbieriDPedulliMGambettiDGhidoniIRigatelliMFC28-04 - Quality of life assessment after cardiac surgery in octogenarians: Is it really feasible?Eur Psychiatry2619742011http://www.em-consulte.com/article/289736/fc28-04-quality-of-life-assessment-after-cardiac-s10.1016/S0924-9338(11)72086-7 MasséLAntonacciMLow cardiac output syndrome: Identification and managementCrit Care Nurs Clin North Am17375383200510.1016/j.ccell.2005.07.00516344207 AlgarniKDMagantiMYauTMPredictors of low cardiac output syndrome after isolated coronary artery bypass surgery: Trends over 20 yearsAnn Thorac Surg9216781684201110.1016/j.athoracsur.2011.06.01721939957 ManganoDTHollenbergMFegertGMeyerMLLondonMJTubauJFKrupskiWCThe Study of Perioperative Ischemia (SPI) Research Group: Perioperative myocardial ischemia in patients undergoing noncardiac surgery - I: Incidence and severity during the 4 day perioperative periodJ Am Coll Cardiol17843850199110.1016/0735-1097(91)90864-61999618 HeXMChenLLuoJBFengXXZhangYBChenQJJiXLWangTSEffects of rhBNP after PCI on non-invasivehemodynamic in acute myocardial infarction patients with left heart failureAsian Pac J Trop Med9791795201610.1016/j.apjtm.2016.06.00627569890 TargońskaSKoziołMMCzajkowskiMStążkaJKozioł-MontewkaMSternal wound complications after cardiac surgery - a case reportWiad Lek6895982015(In Polish)26094341 KerneisCKLafargeALLarnierLLScalbertFBrussetABEstagnasiePESquaraPSBowel and related complications after cardiac surgeryCrit Care19Suppl 1P375201510.1186/cc14455 HowellNJAshrafianHDruryNERanasingheAMContractorHIsacksonHCalvertMWilliamsLKFreemantleNQuinnDWGlucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: Results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) trialCirculation123170177201110.1161/CIRCULATIONAHA.110.94517021200004 HowardBTIlesTLColesJASiggDCIaizzoPAReversible and irreversible damage of the myocardium: Ischemia/reperfusion injury and cardioprotectionHandbook of Cardiac Anatomy, Physiology, and Devices3rd editionSpringer International PublishingNew York201510.1007/978-3-319-19464-6_42 MadamanchiCAlhosainiHSumidaARungeMSObesity and natriuretic peptides, BNP and NT-proBNP: Mechanisms and diagnostic implications for heart failureInt J Cardiol176611617201410.1016/j.ijcard.2014.08.00725156856 OremusMDon-WauchopeAMcKelvieRSantaguidaPLHillSBalionCBoothRBrownJAAliUBustamamABNP and NT-proBNP as prognostic markers in persons with chronic stable heart failureHeart Fail Rev19471505201410.1007/s10741-014-9439-624986335 BoerBPVieiraMLSampaioROAbensurHOliveiraAGFernandesJRGrinbergMCorrelation to NT-ProBNP and remodeling after cardiac surgeryArq Bras Cardiol100469475201323579620 Recombinant Human Brain Natriuretic Peptide Multicenter Clinical Study GroupHuDYEfficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with decompensated acute heart failure: A multicenter, randomized, open label, controlled studyZhonghua Xin Xue Guan Bing Za Zhi393053082011(In Chinese)21624304 XingKFuXWangYLiWGuXHaoGMiaoQLiSJiangYFanWEffect of rhBNP on renal function in STEMI-HF patients with mild renal insufficiency undergoing primary PCIHeart Vessels31490498201610.1007/s00380-015-0642-825637044 ZhangSWangZEffect of recombinant human brain natriuretic peptide (rhBNP) versus nitroglycerin in patients with heart failure: A systematic review and meta-analysisMedicine (Baltimore)95e4757201610.1097/MD.000000000000475727858837 ZhuXQHongHSLinXHChenLLLiYHChanges in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptideBraz J Med Biol Res47646654201410.1590/1414-431X2014347425014176 ZhangJZhangLWuQLiuHHuangLRecombinant human brain natriuretic peptide therapy combined with bone mesenchymal stem cell transplantation for treating heart failure in ratsMol Med Rep7628632201310.3892/mmr.2012.118523165804 BakkehaugJPKildalABEngstadETBoardmanNNæsheimTRønningLAasumELarsenTSMyrmelTHowOJResponse to letter regarding article, ‘Myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity’Circ Heart Fail81142201510.1161/CIRCHEARTFAILURE.115.00254826738203 LyuTZhaoYZhangTZhouWYangFGeHDingSPuJHeBNatriuretic peptides as an adjunctive treatment for acute myocardial infarction: Insights from the meta-analysis of 1,389 patients from 20 trialsInt Heart J55816201410.1536/ihj.13-10924463927

Cardiac output of two groups at different time points.

Pulmonary capillary wedge pressure (PAWP) of two groups at different time points.

Central venous pressure (CVP) of two groups at different time points.

Baseline data of two groups.

Item Observation group n=75 Control group n=75 t/χ2 P-value
Age (years) 30–68 30–65
Sex (male/female) 39/36 34/41 0.053 0.513
Average age (years) 43.56±6.42 43.85±6.53 0.274 0.784
BMI (kg/m2) 22.13±3.45 22.76±3.38 1.130 0.261
Operation type (n, %) 0.042 0.874
  Valve repair or replacement 29 (38.67) 31 (41.33)
  Correction of congenital heart disease 19 (25.33) 20 (26.67)
  Coronary artery and major blood vessel related surgery 27 (36.00) 24 (32.00)
Preoperative cardiac function (NYHA) 0.027 0.739
  Grade II (n, %) 32 (42.67) 29 (38.67)
  Grade III (n, %) 43 (57.33) 46 (61.33)

Comparison of NT-proBNP levels in two groups.

Group No. of cases Before operation Before medication after operation Seven days after medication F-value P-value
Observation group 75 1315.35±221.14 1934.06±321.13 472.23±51.02 76.312 <0.001
Control group 75 1326.06±231.23 1963.73±335.25 1062.76±311.17 75.431 <0.001
t-value 0.290 0.129 16.219
P-value 0.772 0.897 <0.001

Comparison of changes of LVEF in two groups.

Group No. of cases Before operation Before medication after operation Seven days after medication F-value P-value
Observation group 75 43.35±3.14 50.06±3.13 56.23±3.02 9.432 <0.001
Control group 75 43.06±3.23 49.73±3.25 51.76±3.17 7.581 <0.001
t-value 0.558 0.633 8.842
P-value 0.578 0.527 <0.001

Comparison of ventilator support and ICU indwelling time and postoperative complications of two groups of patients.

Group No. of cases Ventilator support time (h) ICU indwelling time (h) Postoperative complication (n,%)
Observation group 75 12.15±1.34 26.16±3.33 4 (5.33)
Control group 75 16.76±1.53 36.83±3.45 13 (17.33)
t-value 19.630 19.271 4.247
P-value <0.001 <0.001 0.039

Comparison of vital signs in two groups of patients during perioperative period.

Group No. of cases SBP (mmHg) DBP (mmHg) HR (beats/min) SaO2 (%)
Observation group 75 115.35±3.14 64.06±3.13 90.06±8.17 98.23±1.02
Control group 75 108.06±3.23 59.73±3.25 95.62±9.29 94.76±1.17
t-value 14.015 8.311 3.899 19.360
P-value <0.001 <0.001 0.0001 <0.001